In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Daiichi Sankyo acquires majority of Zenotech for R782.4mm

Executive Summary

A year after postponing an open offer that started in early 2009 for Zenotech Laboratories Inc., Daiichi Sankyo Co. Ltd. has now completed the acquisition of an additional 20% of the public Indian biogeneric firm for R782.4mm ($16.9mm), or R113.62 per share--an 11% premium over Zenotech's average prior to the January 2009 announcement. Daiichi's Ranbaxy Laboratories Ltd. subsidiary now owns 67% of Zenotech.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies